Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by. This is RG, your conference operator today. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would like now to turn the conference over to Helen Robinson, Vice President of Investor Relations and Communications. Please go ahead. Good afternoon, and thank you for joining Numora Therapeutics' second quarter 2025 financial results conference call. Before we begin, I encourage everyone to go to the investors and media section of our website at numoratx.com, where you can find the press release related to today's call. With me today from Numora are Chief Executive Officer Paul Burns, President Josh Pinto, Chief Operating and Development Officer Bill Arora, Chief Scientific Officer Nick Brandon, and Chief Financial Officer Mike Milligan. I'd like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please review the risk factors discussed in today's press release and in our SEC filings for additional detail. With that, I'll now turn the call over to Paul. Thanks, Helen. Good afternoon, everyone, and thank you for joining us. At Numora, we are on a mission to address the largest population health challenges of our generation and to do so at scale. To achieve that goal, we know that we need to generate better medicines, therapies that enable better outcomes, that meaningfully improve the treatment of prevalent diseases, and ultimately that positively impact quality of life for patients and their familie...